AlphAIAlphAI — Financial news for AI agents
finance.yahoo.comOCT 222 min read$BIIB

Biogen +5% on BofA Price Target Hike Ahead of “Relatively Quiet” Q3

Biogen (BIIB) shares rose 5% after BofA increased its price target to $244, maintaining a Neutral rating. The stock now trades above both BofA's and TD Cowen's targets. Analysts expect 6% revenue growth this year, with a forward P/E near its five-year high. Biogen reports Q3 results on Oct. 28.

Original reporting
finance.yahoo.com
Published Oct 22, 2026, 8:52 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 22, 2026, 9:12 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Biogen +5% on BofA Price Target Hike Ahead of “Relatively Quiet” Q3 — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$BIIBBullishMed
01

Why it matters

The price target increase reflects confidence in Biogen's pipeline and recent revenue trends, but the stock remains near a five‑year high forward P/E.

02

Market read

Biogen's 5% rally driven by analyst target hike offers a short‑term buying opportunity ahead of earnings.

03

What to watch

Biogen's slow revenue growth and high forward P/E could limit upside.

Relevance 7/10Novelty 7/10Timing: pre‑market today

Background

Biogen is awaiting its Q3 earnings on Oct. 28; analysts have been raising targets amid modest growth expectations.

Company-level read

Ticker impact

$BIIBBullishHigh confidence
Context

BofA raised Biogen's price target to $244 from $219, prompting a 5% share rise.

Expected impact

upward pressure as the market prices in the higher target

Evidence & confidence

The new target is close to consensus and follows a recent upgrade, supporting further buying.

Market effects

Sector

Healthcare sector may benefit from analyst optimism on Biogen.

Regional

U.S. market focus on biotech earnings and guidance.

Global

Limited to U.S. biotech investors.

Counterpoint

What could challenge this read

Target hikes may be premature if upcoming Q3 results miss expectations.

Key entities

  • company
    Biogen

    U.S. biotech firm (ticker BIIB).

  • analyst
    Bank of America

    Raised price target to $244.

Read at source← All news

Related articles

OCT 19
$BIIBMed

Biogen to present 76-week Empaveli data at kidney conference

Biogen Inc. (BIIB) will present 76-week data on Empaveli and investigational drug felzartamab at the American Society of Nephrology Kidney Week. The data shows sustained proteinuria reduction and kidney function stabilization in patients with C3 glomerulopathy and primary immune-complex membranoproliferative glomerulonephritis. Empaveli's indication was recently expanded by the FDA. Felzartamab is being studied in multiple Phase 3 trials, with data expected in 2027.

investing.com2 min
OCT 19
$BIIBMed

Biogen to Present New Data Across Nephrology Portfolio, Including Long-term EMPAVELI® (pegcetacoplan) Phase 3 Results, at American Society of Nephrology (ASN) Kidney Week | Biogen

Biogen (BIIB) will present new data on EMPAVELI (pegcetacoplan) and felzartamab at ASN Kidney Week. EMPAVELI showed sustained proteinuria reduction and eGFR stabilization in C3G and IC-MPGN over 76 weeks. Felzartamab is being studied in three Phase 3 trials for kidney diseases. Biogen aims to address unmet needs in nephrology.

investors.biogen.com2 min
OCT 19
$BIIBLow

Biogen Inc. (BIIB) To Present 76-Week EMPAVELI Kidney Data at ASN

Biogen Inc. will present 76-week data on EMPAVELI at the ASN conference, showing sustained proteinuria reduction and eGFR stabilization in kidney diseases. The company will also share updates on felzartamab, an investigational drug for immune-mediated kidney diseases. Biogen recently expanded EMPAVELI's U.S. label to include kidney function loss reduction.

tradingview.com1 min